Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma.
INTRODUCTION
Glioblastoma, the most aggressive and most common primary brain tumor in adults, [1] [2] [3] is an intensely vascularized, invasive tumor with a high propensity to induce angiogenesis. 4 The standard of care for newly diagnosed glioblastoma includes surgical resection where feasible, involved-field radiotherapy (RT) and concomitant temozolomide (TMZ) chemotherapy followed by up to 6 months of adjuvant TMZ (TMZ/RT3 TMZ). 5 Methylation of the O 6 -methylguanine-DNA methyltransferase (MGMT) promoter is a putative predictive marker for benefit from TMZ plus RT. [6] [7] [8] Despite these diagnostic and therapeutic advances, most patients with glioblastoma still die within 2 years.
Cilengitide (EMD 121974; Merck KgaA, Darmstadt, Germany) is the first agent in a novel class of integrin-directed anticancer therapies to reach the clinic. 9 Integrins are heterodimeric transmembrane receptors that play a key role in cellular interactions, adhesion to the extracellular matrix, and cell migration. 10 Cilengitide is a cyclized arginineglycine-aspartic acid-containing pentapeptide that
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selectively binds the cell surface receptors ␣ V ␤ 3 and ␣ V ␤ 5 , which are expressed on activated endothelial cells during angiogenesis. 11, 12 Moreover, cilengitide may act directly on ␣ V ␤ 3 -and ␣ V ␤ 5 -expressing tumor cells, depriving them of important signals involved in survival and growth and may act indirectly by inhibiting angiogenesis and thereby tumor growth. 13, 14 Glioblastomas express the target integrins of cilengitide on activated endothelial cells and on tumor cells. 15 Phase I and II studies of single-agent cilengitide in patients with recurrent glioblastoma have demonstrated an excellent safety profile with little toxicity and promising antitumor activity. [16] [17] [18] Preclinical models indicated a synergistic effect when cilengitide is combined with RT 19, 20 or with an alkylating agent (data on file, Merck KGaA, Darmstadt, Germany). There is thus a strong scientific rationale for combining cilengitide with chemoradiotherapy to improve tumor control and inhibit tumor cell adhesion and migration. This study investigated the efficacy and safety of concomitant and adjuvant cilengitide added to standard chemoradiotherapy in patients with newly diagnosed glioblastoma.
PATIENTS AND METHODS

Study Design
This multicenter, single-arm, phase I/IIa trial investigated the efficacy and safety of cilengitide added to TMZ/RT3 TMZ in patients with newly diagnosed glioblastoma. It was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and International Conference on Harmonisation recommendations. The study protocol and informed-consent form were approved by ethics committees at each site in accordance with local legislation. Written informed consent was obtained from patients before study entry. The primary end point was the progression-free survival (PFS) rate at 6 months. Secondary end points were overall survival (OS), safety, and pharmacokinetics. The influence of MGMT promoter methylation status on efficacy was investigated in a prospectively planned subgroup analysis.
Patients
Main inclusion criteria were age Ն 18 to Յ 70 years; newly diagnosed, histologically proven supratentorial glioblastoma (WHO grade 4); Eastern Cooperative Oncology Group (ECOG) performance status Յ 2; and adequate renal function (creatinine Յ 1.5ϫ upper limit of normal [ULN] or creatinine clearance Ն 60 mL/min), hepatic function (total bilirubin Յ 1.5ϫ ULN and serum transaminases Յ 2.5ϫ ULN), and hematologic function (absolute neutrophil count Ն 1,500/L, platelets Ն 100,000/L, and hemoglobin Ն 10 g/dL). Tumor tissue was required for central pathology review and MGMT promoter methylation analysis. An interval of Ն 3 weeks but Յ 5 weeks between surgery or biopsy and enrollment was required.
Exclusion criteria were prior chemotherapy, antiangiogenic therapy, RT, or a history of malignancy in the previous 5 years. Patients with planned surgery for other diseases, a history of peptic ulcer within the last 6 months, or a history of coagulation disorder associated with bleeding or recurrent thrombotic events were also excluded. A negative pregnancy test and adequate contraception were mandatory.
Treatment
RT and TMZ were administered as previously described. 5 Fractionated three-dimensional conformal RT was delivered with a linear accelerator at 2 Gy per fraction for a total of 60 Gy in 30 fractions (5 d/wk). Target volume was planned from postoperative magnetic resonance imaging (MRI) studies and included all gross disease plus a margin of 2 to 3 cm. TMZ at 75 mg/m 2 /d was administered orally 7 days each week from the first to the last day of RT. After a 4-week break, adjuvant TMZ at 150 to 200 mg/m 2 /d was given for 5 consecutive days every 4 weeks for a total of six cycles.
Cilengitide at 500 mg was administered as a 1-hour intravenous infusion twice weekly on days 1 and 4 (occasionally on days 2 and 5), starting 1 week before chemoradiotherapy and continuing until progression or the end of adjuvant TMZ (ie, for up to 35 weeks). It was administered approximately 2 hours before TMZ; RT was delivered approximately 60 minutes after TMZ.
Pharmacokinetics
Pharmacokinetic analyses were performed in a subset of 13 patients (three patients received enzyme-inducing antiepileptic drugs (EIAEDs), six patients received non-EIAEDs, and four patients received no anticonvulsants). Blood samples (4 mL) were taken to determine plasma concentrations of cilengitide before dosing and at 1, 1.5, 2, 3, 4, 8, and 24 hours after starting the infusion on day 1 of weeks 1, 2, 8, and 12. The same blood samples were used to determine plasma concentrations of TMZ before dosing and at 0.25, 0.5, 1, 2, 3, 4, 6, and 8 hours after administration on days 3 and 4 of week 2. Plasma concentrations were determined using validated high-performance liquid chromatography and liquid chromatography tandem mass spectrometry. 21, 22 The pharmacokinetic parameters of cilengitide and TMZ were calculated from plasma concentration data according to noncompartmental standard methods using the pharmacokinetics software program KINETICA.
MGMT Status
MGMT gene promoter methylation status was determined by methylation-specific polymerase chain reaction (PCR), as previously described.
7,23 Genomic DNA was isolated from macrodissected paraffin sections (Ex-Wax DNA Extraction Kit S4530; Chemicon, Temecula, CA) or cryosections of glioblastoma tissue (Qiagen genomic kit; Qiagen, Hombrechtikon, Switzerland) and subjected to bisulfite modification using the EpiTect kit (Qiagen). Unmethylated cytosine, but not its methylated counterpart, is modified into uracil by bisulfite treatment. Methylation-specific PCR was performed in a nested two-step approach. The results were confirmed in an independent experiment, starting with reisolation of DNA from the tumor. PCR products were separated on 4% agarose gels.
Efficacy and Safety Assessments
A baseline gadolinium-enhanced MRI scan was performed within 1 week before the first dose of cilengitide for patients who had undergone a tumor biopsy or less than 48 hours after surgery for patients who had undergone open tumor resection. MRI was repeated 3 to 4 weeks after the end of RT and every 8 weeks thereafter for 6 months and subsequently every 3 months. Progression was based on investigators' clinical and radiologic assessment according to Macdonald criteria. 24 Safety was evaluated by descriptively summarizing adverse events (AEs), laboratory assessments, and physical examinations, including ECOG performance status, neurologic examinations, hematology and coagulation parameters, weekly blood counts, serum chemistry, urinalysis, chest x-ray, and ECG. All AEs were recorded according to Common Toxicity Criteria version 3.0, and AEs possibly related to treatment with chemoradiotherapy or cilengitide or not otherwise attributed were reported as treatment-related AEs.
Statistical Methods
All analyses were performed on the intent-to-treat population defined as all patients who received at least one dose of cilengitide. The primary end point was PFS rate at 6 months. PFS was defined as time from start of cilengitide treatment until progression or death from any cause. In a sample of 50 patients, the target was to obtain a 6-month PFS rate of Ն 65%. OS was defined as time from start of cilengitide treatment until death from any cause. KaplanMeier survival curves (product-limit estimates) were produced with a summary of associated statistics (median survival time, 6-month survival rate estimates) including the corresponding two-sided 95% CIs. status (n ϭ 1), or withdrawal of consent (n ϭ 1). Patient characteristics are summarized in Table 1 . Median age was 57 years, and most patients had a performance status of 0 or 1. Surgery was reported as gross total resection in 23, partial resection in 20, and stereotactic biopsy in nine patients. Thirty-six patients received antiepileptic drugs (AEDs) at baseline, including 17 patients receiving EIAEDs. Histology was confirmed as glioblastoma in 92% of patients, while two tumors were considered anaplastic astrocytoma (WHO grade 3); confirmation of the diagnosis was not possible in two patients because of insufficient or missing samples. MGMT promoter methylation status was determined in 45 patients (87%) and approximately half 23 had MGMT promoter methylation, a distribution comparable to that in our previous trials. [6] [7] [8] 
Treatment Delivery
Fifty patients (96%) completed combination treatment with cilengitide plus concomitant TMZ/RT; 23 patients (44%) completed the planned study period of 35 weeks, including all six cycles of maintenance TMZ. Reasons for early discontinuation were disease progression (19 patients; 37%), AEs (nine patients; 17%), or withdrawal of consent (one patient; 2%).
Efficacy
After a median follow-up of 34 months (minimum follow-up, 24 months), 43 patients (83%) progressed and 34 patients (65%) died ( Table 2 ). The 6-month PFS rate (primary end point) was 69% (95% CI, 54% to 80%), median PFS was 8.0 months (95% CI, 6.0 to 10.7 months), median OS was 16.1 months (95% CI, 13.1 to 23.2 months), and 1-and 2-year OS rates were 68% (95% CI, 53% to 79%) and 35% (95% CI, 22% to 48%), respectively.
Subgroup analyses for known clinical prognostic factors demonstrated prolonged PFS and OS in patients younger than age 50 years and in those who had debulking surgery. PFS was significantly longer in patients with tumors with MGMT promoter methylation than in those without (Fig 1; Table 2 ). OS was also prolonged in patients with MGMT promoter methylation (Fig 2, Table 2 ).
Pharmacokinetics
Mean plasma concentration-time curves and pharmacokinetic parameters for cilengitide and TMZ are depicted in Figure 3 and summarized in Appendix Tables A1 and A2 (online only) . Mean cilengitide plasma concentration/time profiles and mean pharmacokinetic parameters (maximum plasma concentrations [C max ], ]) were similar throughout treatment, indicating that cilengitide pharmacokinetic parameters are independent of time and not influenced by cotreatment with TMZ, TMZ chemoradiotherapy, or TMZ chemoradiotherapy plus EIAEDs.
Cilengitide C max was reached at 1 hour postdose (ie, the end of infusion). Mean systemic cilengitide CL ranged from 6.72 to 7.51 L/h, t 1/2 ranged from 2.02 to 2.16 hours, and V z ranged from 19.6 to 21.9 L, nominally equivalent to the extracellular fluid volume. There was no apparent accumulation of cilengitide with repeated administration.
TMZ plasma concentration/time profiles and mean PK parameters were also similar throughout treatment, indicating that TMZ pharmacokinetics are not influenced by concomitant cilengitide. TMZ C max was reached within 1 hour after oral administration. Mean systemic TMZ CL was 7.42 L/h/m 2 on day 3 and 7.56 L/h/m 2 on day 4; mean t 1/2 was 1.84 hours on both days; and V z was 19.7 L/m 2 on day 3 and 20.1 L/m 2 on day 4. Overall, the pharmacokinetic parameters of TMZ were in good agreement with published data 25 and did not appear to be influenced by concomitant treatment with cilengitide and RT.
Safety
The combination of cilengitide with standard chemoradiotherapy was safe and well tolerated. Treatment-related AEs were usually mild to moderate (Table 3 and Appendix Table A1 ) and in the range previously observed with TMZ/RT3 TMZ alone. 5 Constitutive symptoms (nausea, headache, fatigue, vomiting, anorexia) were the most common nonhematologic AEs. Nine patients discontinued treatment because of intercurrent events or AEs. In seven patients (14%), this was considered possibly treatment-related: (thrombocytopenia (two patients), intracranial hemorrhage (one patient), neuropathy (one patient), and idiosyncratic liver toxicity (one patient). Thromboembolic events were observed in three patients. One thrombosis unlikely related to treatment and further complicated by a fatal intracranial bleed occurred after the end of study treatment 18 days after the last cilengitide administration. A minor intracranial hemorrhage was detected on MRI in one patient after a seizure. One patient with a history of diverticulosis required surgery for intestinal perforation; cilengitide therapy was subsequently resumed without further complications. Grade 1/2 hypertension was observed in five patients (9.6%) and mild proteinuria in one patient. Other toxicities were one case each of reversible peripheral grade 2 neuropathy not otherwise explained and idiosyncratic liver toxicity likely related to valproic acid. 26 One patient died because of tumor progression within 28 days of the last dose of cilengitide. No safety differences were observed between patients with versus without MGMT promoter methylation (data not shown). 
DISCUSSION
Various strategies have been pursued to improve the outcome for newly diagnosed glioblastoma patients by adding new agents to standard chemoradiotherapy. Here, we report for the first time (to the best of our knowledge) the use of an integrin inhibitor in newly diagnosed glioblastoma. The addition of cilengitide to the combined chemoradiotherapy regimen showed clinical activity and was well tolerated. The slightly higher number of patients discontinuing therapy early following possibly treatment-related AEs (14%) compared with the European Organisation for Research and Treatment of CancerNational Cancer Institute of Canada (EORTC-NCIC) experience (11%) 5 may be explained by the increased monitoring because of the twice weekly administration schedule. Overall, the toxicity of the new combination treatment was comparable to prior experience with TMZ/RT3 TMZ alone, 5 and also in line with other reports for cilengitide. [16] [17] [18] 27 There was no pattern of AEs, and no single AE could be specifically attributed to the cilengitide. Thromboembolic and hemorrhagic complications appeared to not increase after the addition of this integrin inhibitor with antiangiogenic properties.
Of note, no severe hemorrhagic complications or wound-healing problems were observed in this population of patients treated shortly after brain surgery, similar to observations in another phase II study in which cilengitide was administered before surgery at recurrence.
16
The pharmacokinetics of cilengitide and of TMZ in combination with RT were comparable to published data on these drugs as single agents, 21, 22, 25 and no pharmacokinetic interaction or accumulation after repeated dosing was observed. Cilengitide is mainly excreted by the kidneys as unchanged drug; no interaction with EIAEDs was observed, consistent with previous observations. 18 The primary end point, the 6-month PFS rate, was 69% (95% CI, 54% to 80%)-an improvement of approximately 15% over TMZ/ RT3 TMZ alone 5 -and thus met the predefined target of success of Ͼ 65%. After a minimum follow-up of 2 years, six patients had not progressed. OS also compares favorably with previous reports, with a median of 16.1 months (95% CI, 13.1 to 23.2 months) and a 2-year survival rate of 35% (95% CI, 22% to 48%). A better outcome was seen in patients who had undergone debulking surgery. In the context of treatment with drugs such as cilengitide, it is reasonable to assume that the inhibition of attachment and migration may become clinically relevant mainly after elimination of the tumor bulk.
The benefit of adding cilengitide at the dose and schedule reported here to the standard TMZ/RT3 TMZ appears to be limited to patients with glioblastoma with MGMT promoter methylation. The reasons for this nonintuitive interrelation remain unclear. No synergistic effects were identified for the combination of cilengitide and TMZ in vitro, and the MGMT status per se had no effect on the biologic activity of cilengitide. 13 We speculate that cilengitideinduced vascular normalization improves the delivery of TMZ to tumor tissue, with a preferential benefit for patients with MGMT promoter methylation. This is in accordance with the observation of a better prognosis associated with increased expression of a signature for tumor endothelium markers in the treatment arm of the EORTC-NCIC study, which may be linked to a better perfusion of the tumor with TMZ.
28
Could the favorable results be related to an increased incidence of pseudoprogression in patients with MGMT-methylated tumors 29 that was successfully treated by cilengitide? We believe that this is not the case. In fact, it remains to be confirmed that patients with MGMT promoter methylation are more likely to experience pseudoprogression, and unlike the case of vascular endothelial growth factor antibody bevacizumab, 30 there are no data to suggest that cilengitide will ameliorate treatment-induced imaging changes in glioblastoma.
Orthotopic in vivo glioblastoma models demonstrated both sensitivity to cilengitide 20 and striking synergy between cilengitide and RT. 19 One may speculate that patients without MGMT promoter methylation may require doses higher than 500 mg to experience such a radiosensitizing effect. We used a 500-mg dose based on findings from a prior phase I dose-escalation study, in which dose-limiting toxicity was not reached at doses up to 2,400 mg/m 2 and responses were observed at both lower and higher doses. 18 However, there is now increasing evidence that cilengitide was underdosed in our trial: A randomized trial that evaluated tissue penetration of cilengitide in patients treated before surgery for recurrent disease demonstrated higher drug concentrations in the tumor tissue at 2,000 mg of cilengitide compared with 500 mg only. 17 Two randomized phase II studies evaluated a lower (500 mg) and higher (2,000 mg) cilengitide dose in recurrent and newly diagnosed glioblastoma; both trials consistently showed a better outcome for patients treated at the 2,000-mg dose level. 16, 27 In newly diagnosed glioblastoma patients, therapy with cilengitide in addition to TMZ/RT3 TMZ demonstrated a median survival of 17 months and 21 months for the 500-mg and 2,000-mg doses, respectively.
27
Despite encouraging clinical activity throughout all phase I and II trials, preclinical observations have recently provoked controversy about paradoxical promotion of angiogenesis and metastasis at extremely low doses. 31 At the dose used in our regimen, sufficiently high tissue concentrations of cilengitide are achieved.
32
On the basis of the results of this trial and supportive data from complementary trials and preclinical and clinical studies, a randomized phase III trial (CENTRIC, EORTC 26071-22072, NCT00689221) was launched in 2008. The standard arm corresponds to standard TMZ/RT3 TMZ chemoradiotherapy 5 whereas the experimental arm investigates the addition of high-dose (2,000 mg) cilengitide to TMZ/ RT3 TMZ. Eligibility is restricted to patients with a methylated MGMT promoter, speculating that this antiangiogenic strategy is most effective in the presence of an active chemotherapy regimen. The excellent safety profile and the observation of some early relapses after cessation of cilengitide suggest that the discontinuation of cilengitide after completion of 6 months in the trial reported here may have been premature. Indeed, mechanistic considerations warrant prolonged integrin inhibition. Accordingly, cilengitide will be administered until progression or for up to 18 months in the CENTRIC trial. 
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